Charles River Completes the Acquisition of Vigene Biosciences
The acquisition of Vigene Biosciences, a leading contract development and manufacturing organization (CDMO) providing viral vector-based gene delivery solutions, strengthens our ability to support our clients with end-to-end cell and gene therapy support.
Vigene has significant expertise in CGMP viral vector manufacturing of adeno-associated viruses (AAV), the most commonly used delivery solution for gene therapies, as well as other major viral vectors, including lentivirus, retrovirus and adenovirus. Vigene also specializes in producing high-quality, research grade, and CGMP plasmid DNA, a fundamental tool used in the development of viral vectors for gene-modified cell therapies, gene therapies, and vaccine production.
With operations based in Rockville, Maryland, Vigene expands and complements our viral vector and plasmid DNA offerings in Europe (added earlier this year with the acquisition of Cobra Biologics). When combined with our integrated portfolio of Biologics Testing Solutions, our clients will find value and save time with this comprehensive solution from discovery and non-clinical development through CGMP manufacturing in advanced drug modalities.
“We understand that providing our clients access to a single cell and gene therapy service provider with the capacity and expertise to deliver, is critical to success” explains Kerstin Dolph, CVP, Global Biologics, “this new acquisition reinforces our commitment to providing full-service solutions for therapeutic antibody and cell and gene therapy organizations”.
Interested to learn more? Consult an expert.